Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
29 janv. 2024 08h30 HE
|
Vaxcyte, Inc.
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of...
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc....
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
04 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability...
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
04 déc. 2023 18h35 HE
|
Vaxcyte, Inc.
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or...
Vaxcyte Appoints Jacks Lee to Board of Directors
28 nov. 2023 08h30 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of...
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
27 nov. 2023 16h00 HE
|
Vaxcyte, Inc.
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing...
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
09 nov. 2023 08h30 HE
|
Vaxcyte, Inc.
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second...
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
06 nov. 2023 16h03 HE
|
Vaxcyte, Inc.
-- Completed Successful End-of-Phase 2 Meeting with FDA for VAX-24; Topline Phase 3 Data in Adults Expected in 2025 -- -- Received FDA Clearance of VAX-31 Adult IND Application; Phase 1/2 Study...
Vaxcyte to Present at Upcoming Investor Conferences
31 oct. 2023 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
19 oct. 2023 08h30 HE
|
Vaxcyte, Inc.
-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second...